GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2211-2216

  Bhattarai, Nirjal ^a,b,c   McLinden, James H ^a,b   Xiang, Jinhua ^a,b   Kaufman, Thomas M ^a,b   Stapleton, Jack T ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; DOXYCYCLINE; GLYCOPROTEIN E2; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; STAT5A PROTEIN; T LYMPHOCYTE RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPATITIS GB VIRUS A; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STEADY STATE;

GB VIRUS C; HUMANS; INTERLEUKIN-2; JURKAT CELLS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84865403730     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201324     Document Type: Article

References (48)

1. Stapleton, J. T., S. Foung, A. S.Muerhoff, J. Bukh, and P. Simmonds. 2011. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBVD in genus Pegivirus within the family Flaviviridae. J. Gen. Virol. 92: 233-246.
2. Mohr, E. L., and J. T. Stapleton. 2009. GB virus type C interactions with HIV: the role of envelope glycoproteins. J. Viral Hepat. 16: 757-768.
3. Stapleton, J. T. 2003. GB virus type C/Hepatitis G virus. Semin. Liver Dis. 23: 137-148.
4. Stapleton, J. T., C. F. Williams, and J. Xiang. 2004. GB virus type C: a beneficial infection? J. Clin. Microbiol. 42: 3915-3919.
5. Rey, D., J. Vidinic-Moularde, P. Meyer, C. Schmitt, S. Fritsch, J. M. Lang, and F. Stoll-Keller. 2000. High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with human immunodeficiency virus type 1. Eur. J. Clin. Microbiol. Infect. Dis. 19: 721-724.
6. Williams, C. F., D. Klinzman, T. E. Yamashita, J. Xiang, P. M. Polgreen, C. Rinaldo, C. Liu, J. Phair, J. B. Margolick, D. Zdunek, et al. 2004. Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. 350: 981-990.
7. Nunnari, G., L. Nigro, F. Palermo, M. Attanasio, A. Berger, H. W. Doerr, R. J. Pomerantz, and B. Cacopardo. 2003. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann. Intern. Med. 139: 26-30.
8. Xiang, J., S. Wünschmann, D. J. Diekema, D. Klinzman, K. D. Patrick, S. L. George, and J. T. Stapleton. 2001. Effect of coinfection with GB virus C on survival among patients with HIV infection. N. Engl. J. Med. 345: 707-714.
9. Tillmann, H. L., H. Heiken, A. Knapik-Botor, S. Heringlake, J. Ockenga, J. C. Wilber, B. Goergen, J. Detmer, M. McMorrow, M. Stoll, et al. 2001. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345: 715-724.
10. Yeo, A. E., A. Matsumoto, M. Hisada, J. W. Shih, H. J. Alter, and J. J. Goedert. 2000. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann. Intern. Med. 132: 959-963.
11. Lefrère, J. J., C. Férec, F. Roudot-Thoraval, P. Loiseau, J. F. Cantaloube, P. Biagini, M. Mariotti, G. LeGac, and B. Mercier. 1999. GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J. Med. Virol. 59: 32-37.
12. Toyoda, H., Y. Fukuda, T. Hayakawa, J. Takamatsu, and H. Saito. 1998. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17: 209-213.
13. Heringlake, S., J. Ockenga, H. L. Tillmann, C. Trautwein, D. Meissner, M. Stoll, J. Hunt, C. Jou, N. Solomon, R. E. Schmidt, and M. P. Manns. 1998. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J. Infect. Dis. 177: 1723-1726.
14. Björkman, P., L. Flamholc, A. Nauclér, V. Molnegren, E. Wallmark, and A. Widell. 2004. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 18: 877-886.
15. Van der Bij, A. K., N. Kloosterboer, M. Prins, B. Boeser-Nunnink, R. B. Geskus, J. M. Lange, R. A. Coutinho, and H. Schuitemaker. 2005. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J. Infect. Dis. 191: 678-685.
16. Bhattarai, N., and J. T. Stapleton. 2012. GB virus C: the good boy virus? Trends Microbiol. 20: 124-130.
17. Pett, S. L. 2009. Immunotherapies in HIV-1 infection. Curr. Opin. HIV AIDS 4: 188-193.
18. Abrams, D., Y. Lévy, M. H. Losso, A. Babiker, G. Collins, D. A. Cooper, J. Darbyshire, S. Emery, L. Fox, F. Gordin, et al; INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee. 2009. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361: 1548-1559.
19. Sodora, D. L., and G. Silvestri. 2008. Immune activation and AIDS pathogenesis. AIDS 22: 439-446.
20. Pett, S. L., A. D. Kelleher, and S. Emery. 2010. Role of interleukin-2 in patients with HIV infection. Drugs 70: 1115-1130.
21. Nel, A. E. 2002. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J. Allergy Clin. Immunol. 109: 758-770.
22. Fortis, C., L. Soldini, S. Ghezzi, S. Colombo, G. Tambussi, E. Vicenzi, N. Gianotti, S. Nozza, F. Veglia, M. Murone, et al. 2002. Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. AIDS Res. Hum. Retroviruses 18: 491-499.
23. Sereti, I., B. Herpin, J. A. Metcalf, R. Stevens, M. W. Baseler, C. W. Hallahan, J. A. Kovacs, R. T. Davey, and H. C. Lane. 2001. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 15: 1765-1775.
24. Heaton, K. M., G. Ju, and E. A. Grimm. 1993. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 53: 2597-2602.
25. Porter, B. O., J. Shen, J. A. Kovacs, R. T. Davey, C. Rehm, J. Lozier, G. Csako, K. Nghiem, R. Costello, H. C. Lane, and I. Sereti. 2009. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 23: 2015-2019.
26. Kinter, A. L., G. Poli, L. Fox, E. Hardy, and A. S. Fauci. 1995. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J. Immunol. 154: 2448-2459.
27. Morgan, D. A., F. W. Ruscetti, and R. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007-1008.
28. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881-1888.
29. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179: 859-870.
30. Maidana-Giret, M. T., T. M. Silva, M. M. Sauer, H. Tomiyama, J. E. Levi, K. C. Bassichetto, A. Nishiya, R. S. Diaz, E. C. Sabino, R. Palacios, and E. G. Kallas. 2009. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 23: 2277-2287.
31. Schwarze-Zander, C., M. Neibecker, S. Othman, C. Tural, B. Clotet, J. T. Blackard, B. Kupfer, G. Luechters, R. T. Chung, J. K. Rockstroh, and U. Spengler. 2010. GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells. Antivir. Ther. (Lond.) 15: 745-752.
32. Nattermann, J., H. D. Nischalke, B. Kupfer, J. Rockstroh, L. Hess, T. Sauerbruch, and U. Spengler. 2003. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17: 1457-1462.
33. Stapleton, J. T., K. Chaloner, J. Zhang, D. Klinzman, I. E. Souza, J. Xiang, A. Landay, J. Fahey, R. Pollard, and R. Mitsuyasu. 2009. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 23: 605-610.
34. George, S. L., D. Varmaz, and J. T. Stapleton. 2006. GB virus C replicates in primary T and B lymphocytes. J. Infect. Dis. 193: 451-454.
35. Rydze, R. T., N. Bhattarai, and J. T. Stapleton. 2012. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T cell death. Antivir. Ther. In press.
36. Koedel, Y., K. Eissmann, H. Wend, B. Fleckenstein, and H. Reil. 2011. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition. J. Virol. 85: 7037-7047.
37. Jung, S., M. Eichenmüller, N. Donhauser, F. Neipel, A. M. Engel, G. Hess, B. Fleckenstein, and H. Reil. 2007. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 21: 645-647.
38. Xiang, J., J. H. McLinden, T. M. Kaufman, E. L. Mohr, N. Bhattarai, Q. Chang, and J. T. Stapleton. 2012. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. Virology 430: 53-62.
39. Xiang, J., J. H. McLinden, Q. Chang, T. M. Kaufman, and J. T. Stapleton. 2006. An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. Proc. Natl. Acad. Sci. USA 103: 15570-15575.
40. McLinden, J. H., T. M. Kaufman, J. Xiang, Q. Chang, D. Klinzman, A. M. Engel, G. Hess, U. Schmidt, M. Houghton, and J. T. Stapleton. 2006. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J. Virol. 80: 12131-12140.
41. Mohr, E. L., J. Xiang, J. H. McLinden, T. M. Kaufman, Q. Chang, D. C. Montefiori, D. Klinzman, and J. T. Stapleton. 2010. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J. Immunol. 185: 4496-4505.
42. Camargo, J. F., M. P. Quinones, S. Mummidi, S. Srinivas, A. A. Gaitan, K. Begum, F. Jimenez, S. VanCompernolle, D. Unutmaz, S. S. Ahuja, and S. K. Ahuja. 2009. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J. Immunol. 182: 171-182.
43. Cheng, G., A. Yu, and T. R. Malek. 2011. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol. Rev. 241:63-76.
44. Kim, H. P., J. Imbert, and W. J. Leonard. 2006. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17: 349-366.
45. Lin, J. X., and W. J. Leonard. 1997. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 8: 313-332.
46. George, S. L., J. Xiang, and J. T. Stapleton. 2003. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 316: 191-201.
47. Dai, Z., A. Arakelov, M. Wagener, B. T. Konieczny, and F. G. Lakkis. 1999. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death. J. Immunol. 163: 3131-3137.
48. Lenardo, M. J. 1991. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 353: 858-861.